Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage

被引:41
作者
Wiederschain, D
Kawai, H
Shilatifard, A
Yuan, ZM
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[2] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63141 USA
关键词
D O I
10.1074/jbc.M412237200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal translocations involving the mixed lineage leukemia ( MLL) gene are often observed in acute leukemias of both myeloid and lymphocytic origin. Expression of MLL fusion proteins is known to induce malignant transformation of normal blood progenitors; however, molecular mechanisms of this process are still poorly understood. In this study we investigated the effect of several frequently detected MLL fusion proteins on p53 transcriptional activity. Our data show that MLL- AF9, MLL- AF10, MLL- ENL, and MLL- ELL substantially down- regulate p53- mediated induction of p21, MDM2, and Bax in response to DNA damage. Furthermore, we identify the reduction in p53 acetylation by p300 as a major mechanism of the inhibitory effect of MLL leukemic fusions. Our data suggest that abrogation of p53 functional activity can be a common feature of MLL fusion- mediated leukemogenesis.
引用
收藏
页码:24315 / 24321
页数:7
相关论文
共 19 条
[1]   Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].
Ayton, PM ;
Cleary, ML .
ONCOGENE, 2001, 20 (40) :5695-5707
[2]   Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases [J].
Barlev, NA ;
Liu, L ;
Chehab, NH ;
Mansfield, K ;
Harris, KG ;
Halazonetis, TD ;
Berger, SL .
MOLECULAR CELL, 2001, 8 (06) :1243-1254
[3]   PREVALENCE AND CLINICAL CORRELATIONS OF MLL GENE REARRANGEMENTS IN AML-M4/5 [J].
BOWER, M ;
PARRY, P ;
CARTER, M ;
LILLINGTON, DM ;
AMESS, J ;
LISTER, TA ;
EVANS, G ;
YOUNG, BD .
BLOOD, 1994, 84 (11) :3776-3780
[4]   The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds [J].
Caslini, C ;
Alarcòn, AS ;
Hess, JL ;
Tanaka, R ;
Murti, KG ;
Biondi, A .
LEUKEMIA, 2000, 14 (11) :1898-1908
[5]  
CHEN CS, 1993, BLOOD, V81, P2386
[6]   Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain [J].
Gu, W ;
Roeder, RG .
CELL, 1997, 90 (04) :595-606
[7]   MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation [J].
Ito, A ;
Kawaguchi, Y ;
Lai, CH ;
Kovacs, JJ ;
Higashimoto, Y ;
Appella, E ;
Yao, TP .
EMBO JOURNAL, 2002, 21 (22) :6236-6245
[8]   Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region [J].
Kanda, Y ;
Mitani, K ;
Kurokawa, M ;
Yamagata, T ;
Yazaki, Y ;
Hirai, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) :5248-5252
[9]   Deacetylation of p53 modulates its effect on cell growth and apoptosis [J].
Luo, JY ;
Su, F ;
Chen, DL ;
Shiloh, A ;
Gu, W .
NATURE, 2000, 408 (6810) :377-381
[10]   Transcriptional inhibition of p53 by the MLL MEN chimeric protein found in myeloid leukemia [J].
Maki, K ;
Mitani, K ;
Yamagata, T ;
Kurokawa, M ;
Kanda, Y ;
Yazaki, Y ;
Hirai, H .
BLOOD, 1999, 93 (10) :3216-3224